Compare IMCR & CUBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMCR | CUBI |
|---|---|---|
| Founded | 2008 | 1994 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.8B |
| IPO Year | 2016 | 2010 |
| Metric | IMCR | CUBI |
|---|---|---|
| Price | $31.54 | $76.72 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 8 |
| Target Price | $66.33 | ★ $85.00 |
| AVG Volume (30 Days) | ★ 302.8K | 211.8K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 30.39 | 22.99 |
| EPS | 0.23 | ★ 4.02 |
| Revenue | ★ $249,428,000.00 | N/A |
| Revenue This Year | $14.57 | $24.95 |
| Revenue Next Year | $8.21 | $9.50 |
| P/E Ratio | $140.96 | ★ $19.24 |
| Revenue Growth | ★ 43.05 | N/A |
| 52 Week Low | $27.56 | $59.34 |
| 52 Week High | $40.71 | $84.38 |
| Indicator | IMCR | CUBI |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
Customers Bancorp Inc is a bank holding company conducting banking activities through its wholly owned subsidiary, Customers Bank. The Bank provides commercial and consumer customers the stability of a regulated financial institution supported by risk management. It serves commercial and corporate businesses nationwide, including healthcare, real estate, specialty finance, fund finance, technology and venture capital banking, mortgage finance and commercial equipment financing, and provides payments and treasury services. The Bank also serves consumers through its branch network, offering residential mortgages and personal loan and deposit products, including Banking-as-a-Service, with services delivered predominantly in Southeastern and Central Pennsylvania, New York, and other states.